DBV Technologies: FDA Submission for Viaskin Peanut Scheduled for Q3 2026
DBV Technologies has announced the completion of its extensive discussions with the Food and Drug Administration (FDA) regarding the submission of a Biologics License Application (BLA) for its Viaskin Peanut patch for children aged 4 to 7 with peanut allergies. With no additional data requested by the Agency, the French biotech plans to submit the application in the third quarter of 2026.
Structured Exchanges Without Additional Data Requests
DBV conducted structured discussions with the FDA to ensure a comprehensive and efficient review of the upcoming BLA. During these discussions, the U.S. federal agency provided specific feedback on the organization, structuring, and formatting of existing data, particularly regarding Chemical, Manufacturing, and Controls (CMC) elements and biostatistical aspects. The FDA did not request additional data, which is a positive sign for the progression of the application. CEO Daniel Tassé emphasized that the Viaskin Peanut patch remains an innovative and complex product for which there is no regulatory precedent, justifying the thorough nature of these preliminary exchanges.
Submission Planned for the Third Quarter of 2026
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
DBV plans to take the necessary time to integrate all comments from the FDA before submitting the BLA during the third quarter of 2026. This approach is part of a constructive collaboration with the Agency, similar to the exchanges that typically occur after the official submission of a biologics license application. The biotech is organizing a conference call with investors on the same day, June 29 at 5 PM (Eastern Time), to discuss this regulatory progress and answer questions related to the product's trajectory.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1,6 millions de dollars
Quarterly revenue: 1,6 millions de dollars
Net income: -98 millions de dollars
Guidance from the release
DBV is a late-stage biopharmaceutical company currently in regulatory discussions with the FDA, with BLA submission anticipated in Q3 2026; the company reports cash funding into Q3 2027, indicating reliance on capital reserves and no current revenue generation.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
